Dr. David B. Kudrow, MD
Neurology (Neurology Physician)
2001 Santa Monica Blvd, Suite 880w
Santa Moncia, CA 90404
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 65
Licensed in California since 1988, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license G62166 (first issued 1988; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 65
- Services billed
- 4,322
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Telephone medical discussion with physician, 21-30 minutes | 63 | 42 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
| Established patient office or other outpatient visit, 30-39 minutes | 18 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in Santa Moncia, CA | 87 |
| Sumatriptan Succinate Other prescribers in Santa Moncia, CA | 85 |
| Emgality Pen (galcanezumab-gnlm) Other prescribers in Santa Moncia, CA | 65 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Santa Moncia, CA | 44 |
| Amitriptyline Hcl Other prescribers in Santa Moncia, CA | 42 |
| Naratriptan Hcl | 37 |
| Nurtec Odt (rimegepant sulfate) Other prescribers in Santa Moncia, CA | 33 |
| Topiramate Other prescribers in Santa Moncia, CA | 32 |
| Qulipta (atogepant) Other prescribers in Santa Moncia, CA | 27 |
| Verapamil Hcl Other prescribers in Santa Moncia, CA | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 77 payments worth $36,590 in total to this clinician.
| Axsome Therapeutics, Inc. | $35,564 |
|---|---|
| AbbVie Inc. | $700 |
| Pfizer Inc. | $86.10 |
| Lundbeck LLC | $47.35 |
| Merz Pharmaceuticals, LLC | $41.74 |
| Genentech USA, Inc. | $30.37 |
| Lilly USA, LLC | $28.97 |
| Forte Bio-pharma LLC | $28.68 |
| Honoraria | $32,403 |
|---|---|
| Food and Beverage | $2,174 |
| Travel and Lodging | $2,013 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. Jul 17, 2025 | Honoraria Symbravo · Neurology | $11,475 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Honoraria Symbravo · Neurology | $5,738 |
| Axsome Therapeutics, Inc. Nov 13, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Jul 24, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Jul 31, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Nov 12, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Jul 10, 2025 | Honoraria Symbravo · Neurology | $1,519 |
| Axsome Therapeutics, Inc. Nov 6, 2025 | Honoraria Symbravo · Neurology | $1,519 |
| Axsome Therapeutics, Inc. Jun 7, 2025 | Travel and Lodging Symbravo · Neurology · travel to Dallas-Fort Worth, TX · in-kind | $705 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Travel and Lodging Symbravo · Neurology · travel to Danville, CA | $492 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. Nov 13, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Nov 13, 2025 | Travel and Lodging Symbravo · Neurology · travel to Glendale, CA | $26.60 |
| Axsome Therapeutics, Inc. Nov 12, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Nov 12, 2025 | Travel and Lodging Symbravo · Neurology · travel to Brea, CA | $62.30 |
| Axsome Therapeutics, Inc. Nov 6, 2025 | Honoraria Symbravo · Neurology | $1,519 |
| Axsome Therapeutics, Inc. Jul 31, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Jul 31, 2025 | Travel and Lodging Symbravo · Neurology · travel to Thousand Oaks, CA | $49.00 |
| Axsome Therapeutics, Inc. Jul 24, 2025 | Honoraria Symbravo · Neurology | $3,038 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Honoraria Symbravo · Neurology | $11,475 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Honoraria Symbravo · Neurology | $5,738 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Travel and Lodging Symbravo · Neurology · travel to Danville, CA | $492 |
| Axsome Therapeutics, Inc. Jul 17, 2025 | Travel and Lodging Symbravo · Neurology · travel to San Francisco, CA · in-kind | $301 |
| Axsome Therapeutics, Inc. Jul 10, 2025 | Honoraria Symbravo · Neurology | $1,519 |
| Axsome Therapeutics, Inc. Jun 26, 2025 | Travel and Lodging Symbravo · Neurology · travel to Hollywood, CA | $80.00 |
| Axsome Therapeutics, Inc. Jun 26, 2025 | Travel and Lodging Symbravo · Neurology · travel to Dallas, TX | $65.97 |
| Axsome Therapeutics, Inc. Jun 7, 2025 | Travel and Lodging Symbravo · Neurology · travel to Dallas-Fort Worth, TX · in-kind | $705 |
| Axsome Therapeutics, Inc. Jun 7, 2025 | Travel and Lodging Symbravo · Neurology · travel to Dallas, TX · in-kind | $198 |
| Axsome Therapeutics, Inc. Jun 7, 2025 | Travel and Lodging Symbravo · Neurology · travel to Dallas, TX · in-kind | $33.48 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 9 companies. The companies reported $2,145,951 in research payments for these studies, mostly to the institutions running them.
- An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Syn…
Travere Therapeutics, Inc. - A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Cl…
Travere Therapeutics, Inc. - A phase 4 randomized doubleblind placebocontrolled efficacy and tolerability trial of rimegepant for the acute treatment of migraine in adults unsuitable for triptan use
Pfizer Inc. - A phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult par…
AstraZeneca UK Limited - A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of retatrutide once weekly in participants who have obesity or overweight and chronic low back pain (TRIUMPH-7)
Eli Lilly and Company - A phase 4 randomized doubleblind placebocontrolled study to evaluate the efficacy and tolerability of rimegepant for the prevention of migraine in adults with a history of inadequate response to oral preventive medica…
Pfizer Inc. - A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine
Merz Pharmaceuticals, LLC - A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine
Merz Pharmaceuticals, LLC - An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV
Jazz Pharmaceuticals Inc. - A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult …
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.